5244702026-04-012026-06-305244702026-06-305244702026-04-012026-06-30in-capmkt:OtherExpenses1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30in-capmkt:ReportableSegments1Member5244702026-06-30in-capmkt:ReportableSegments1Member5244702026-04-012026-06-30in-capmkt:ReportableSegments2Member5244702026-06-30in-capmkt:ReportableSegments2Member5244702026-04-012026-06-30in-capmkt:ReportableSegments3Member5244702026-06-30in-capmkt:ReportableSegments3Member5244702026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524470SYNCOMFNOTLISTEDINE312C01025SYNCOM FORMULATIONS INDIA LIMITEDMain BoardEquity2026-04-012027-03-312026-08-112026-08-06INRLakhsQuarterlyFirst quarterMulti segment2026-08-1116:00:002026-08-1116:45:00Not applicablefalsefalseNot Applicable2026-04-012026-06-30UnauditedStandalone1246595000781800001324775000587761000173309000-1036110001716670002304000154030001588540001005687000319088000031908800071907000128900073196000024589200000002458920003818700028407900094000000010.260.26000.260.26Others158854000Pharmaceuticals Drugs & Formulations1313578000Trading of Commodities2784000Renting of Properties8413000132477500001324775000Pharmaceuticals Drugs & Formulations313450000Trading of Commodities199000Renting of Properties774300032139200023040000319088000Pharmaceuticals Drugs & Formulations4550008000Trading of Commodities456000Renting of Properties925724000547618800005476188000Pharmaceuticals Drugs & Formulations1056327000Trading of Commodities1250000Renting of Properties284170001085994000010859940001 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11.08.2026 <br /> 1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11.08.2026 <br /> 2 These above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time. <br /> 3 The company is operating in 3 segments ie a Pharmaceuticals Drugs & Formulations b Trading of Commodities c Renting of Property particulars of segment wise results are given as required. <br /> 4 As required under Regulation 33 of SEBI LODR Regulations 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June 2026 The report does not have any impact on the above results and notes which needs explanation. <br /> 5 Previous period figures have been regrouped reclassified wherever necessary to confirm to this period classification. <br /> 6 During the current period, the Company has corrected its method of calculating Earnings Per Share EPS. In previous years or Quarters EPS was calculated considering Total Comprehensive Income. To comply with the requirements of Ind AS 33 the EPS has now been computed using Profit After Tax attributable to equity shareholders. Consequently the comparative EPS for all preceding periods has been restated. There is no restatement in any line items only EPS is restated. The Figurs as Previouly reported and restated are as below <br /> Previously Reported EPS (TCI) Quarter Ended Year Ended <br /> 30-06-2026 31-03-2026 30-06-2025 31-03-2026 <br /> Unaudited Audited Audited Audited <br /> Earnings per equity share (for discontinued & continuing operations) <br /> (1) Basic NA NA 0.21 NA <br /> (2) Diluted NA NA 0.21 NA <br /> Restated EPS (PAT)) <br /> Earnings per equity share (for discontinued & continuing operations) <br /> (1) Basic 0.26 0.26 0.17 0.81 <br /> (2) Diluted 0.26 0.26 0.17 0.81 <br /> 0Item that will be reclassified to profit or loss3818700038187000038187000